Abstract We previously reported that apoptosis is increased m smooth muscle cells cultured from the aorta of spontaneously hypertensive rats versus normotenslve controls. As an mtttal m viva exploration, we now exammed smooth muscle cell apoptosis regulation during the regression of vascular hypertrophy m the thoracic aorta media of spontaneously hypertensive rats receiving the antihypertensive drug enalapnl (30 mg kg-' d-'), losartan (30 mg kg-' d-'), mfedipme (35 mg kg-' d-l), hydralazme (40 mg kg-' d-'), propranolol(50 mg kg-' d-'), or hydrochlorothiazide (75 mg kg-' d-') for 1 to 4 weeks starting at 10 to 11 weeks of age Three criteria were used to evaluate smooth muscle cell apoptosis (1) ohgonucleosomal fragmentation of the extracted aortm DNA, (2) reduction in aortic DNA content, and (3) depletion of smooth muscle cells m the arterial media Arterial DNA synthesis was evaluated by [3H]thymidme mcorporation m viva After 4 weeks of treatment, systohc blood pressure was reduced stgmficantly by >42% wtth losartan, enalapnl, and hydralazme, and by 23% with mfedipme, versus control values of 22025 mm Hg. However, these agents affected vascular growth and apoptosis differently Losartan, enalapnl, and mfedipme stimulated smooth muscle cell apoptosrs threefold to fivefold before there was a significant reduction m DNA synthesis (>25%), vascular mass (>19%), or vascular DNA content (>38%), and these treatments markedly reduced (by 38% to 50%) medial cell number as measured at 4 weeks by the three-dimensional disector method Losartan and mfedipme stimulated smooth muscle cell apoptosis before reducing blood pressure In contrast, hydralazme did not affect vascular mass, apoptosis, or DNA synthesis, although blood pressure was lowered Propranolol or hydrochlorothiazlde failed to affect hypertension or vascular growth Thus, smooth muscle cell apoptosls represents a novel therapeutic target for the control of hypertensive vessel remodeling m response to therapeutic agents (Hypertension. 1997;29[part 2]:340-349.) Key Words l apoptosts l smooth muscle cell . angtotensm II l calcmm channel antagonist S tudies m humans and in experimental models of hypertension have clearly demonstrated the importance of vascular structure m the regulation of blood pressure i-6 Increased vascular mass is an important feature of hypertensive vessels. At the level of small muscular arteries, vascular hypertrophy accompanied by smooth muscle cell (SMC) hypertrophy or hyperplasia acts as an amplifier for elevated vascular resistance and blood pressure.7%8 At the level of the aorta and its main branches, increased mass and ngidtty of the arterial wall contribute to systolic hypertension and represent an mdependent risk factor for left ventricular hypertrophy.9 The remodeling of vascular structure, mcludmg the regression of vascular hypertrophy, is now considered a key therapeutic target in the effort to reduce mortahty and morbidity associated with high blood pressure lo-13
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Increased vascular mass associated with the replication and accumulation of smooth muscle DNA, as in genetttally determmed or secondary hypertension, i4-ls represents a mode of structural remodeling that is less readily reversible than vascular hypertrophy that is solely due to increased protein synthesis without de novo DNA synthesis. Thus, the DNA content of the vessel wall (due to SMC hyperplasia or polyploidy) '6 may be considered as a record of past episodes of vascular growth, contributing to the persistence of the vascular disease. Apoptosrs IS a highly regulated form of programmed cell death that is involved m trssue morphogenesis and homeostasrs as the essential counterpart of cell replication. l9,20 In this context, apoptosts ts potentially mvolved m the regulatton of vascular remodeling, via the deletion of SMC in the vessel wall 20 We have previously reported that the heightened DNA replication of SMC cultured from the aorta of spontaneously hypertensive rats (SHR) occurs m parallel to an increase in apoptosts *r These studies suggested that increased apoptosis may m part counterbalance the heightened cell growth m hypertensive vessels. In this view, the balance between apoptosis and cell (or DNA) rephcation would constttute a key determmant of vascular mass and a potential therapeutic target for achieving longterm regression of vascular hypertrophy. The present studies were designed to investigate whether SMC apoptosts contributes to the regression of vascular hypertrophy during antthypertensive therapy m the SHR. Agents tested belong to several of the maJor classes of drugs used m the clmrc to control elevated blood pressure Our results suggest that SMC apoptosts 1s a novel therapeutic target for the pharmacological control of vascular structure m hypertension
Methods

Drug Treatments
Male SHR weighing 250 to 275 g were purchased from Charles-River (St Constant, Que) and housed for at least 10 days before mmation of drug treatment at 10 to 11 weeks of age Treated rats were given one of the followmg drugs the calcmm channel blocker mfedipme (35 mg kg-' d-'), the anglotensmconvertmg enzyme mhtbltor enalapnl(30 mg kg-' d-'), the AT, receptor antagonist losartan (30 mg kg-' d-'), the smooth muscle relaxant hydralazme (40 mg kg-' *d-l), the P-adrenoceptor deBlois et al Smooth Muscle Cell Apoptosis in Vascular Regression 341 rothiazide (HCT; 75 mg . kg-' .d-I). The doses of antihypertensive drug were chosen on the basis of published reports of others or our own preliminary data showing effectiveness in reducing hypertension or cardiovascular hypertrophy in the SHR.22.2s All drugs were dissolved in the drinking water except for nifedipine, which was mixed with powdered food. The subsets of control rats receiving powdered rat chow without nifedipine showed similar results as the control rats given regular chow in pellets, hence the data from these control groups were pooled for analysis. Food and water, with or without drug, were renewed three times weekly and administered ad libitum. The rats were weighed each week and the dosage of drug adjusted according to their body weight and the amount of water or food consumed. All drugs were from Sigma, except nifedipine, which was provided courtesy of Bayer Canada, Toronto, and losartan and enalapril, which were courtesy of Merck Frosst, Montreal, Canada. The ability of the antihypertensive drugs to reduce aortic hypertrophy was initially examined after 4 weeks of therapy. Drugs that proved effective at 4 weeks were selected for the studies at 2 weeks and 1 week of treatment. An age-matched control group was included in each experiment.
Blood Pressure Measurements
Systolic blood pressure was measured between 8 and 12 AM in each rat by use of the tailcuff plethysmograph method (IITC). Measurements were started 1 week before treatment and performed on conscious, restrained rats previously trained for the procedure. Pressure measurements were made at weekly intervals during the treatment period and at least 2 days before animal sacrifice for tissue isolation to avoid interfering with the vascular growth response.
Tissue Isolation and Vascular Mass Measurements
To evaluate DNA synthesis in vivo, rats were injected IP with [methyl-3H]thymidine (0.5 mCi/kg, New England Nuclear) at 17, 9, and 1 hour before death. Rats were anesthetized with a single IM injection of ketamine (80 mg/kg), xylazine (4 mg/kg), and acepromazine (2 mg/kg), and killed by perfusion of 200 mL isotonic saline via the abdominal aorta. The thoracic aorta was isolated from the diaphragm to above the first intercostal artery and it was cleaned of fat and adventitial connective tissue. The length and wet weight of the aorta were measured before the artery was cut longitudinally to allow removal of the endothelium by scrubbing the intimal surface with a cotton tip applicator. The aorta:body weight ratio was calculated and used as an index of vascular mass. The aortic media was snap frozen in liquid nitrogen and kept at -8O'C until further processing. To further confirm changes in vascular mass, we also measured the cross-sectional area of aortae isolated after 4 weeks of effective antihypertensive therapy (a blindly selected subset of tissues was used for the control and enalapril groups). A 3-mm-long ring of aorta was cut between the third and fourth intercostal arteries after weighing the vessel. The aortic rings were fixed in 4% paraformaldehyde overnight and processed according to routine histological procedures for morphometric measurements in cross-sections of paraffin-embedded arteries. The medial cross-sectional area was evaluated in 5+m-thick, hematoxylin-stained sections of aorta. Photomicrographs of the aorta sections were taken at 200x magnification, digitized, and analyzed using the NIH Image 1.6 image analysis freeware (NIH). Two measures of each tissue section were done to ensure the reproducibility of the image analysis.
DNA Extraction and Characterization
The whole aortic media was homogenized in liquid nitrogen using a mortar and pestle. An aliquot of the pulverized aortic media was weighed and total tissue DNA was extracted by the phenol and chloroform procedure, following tissue digestion steps with proteinase K and RNase A in the presence of EDTA, as described previously.26 DNA concentration was determined by spectrophotometry and total DNA content per unit of aortic length was calculated using the following equation: total aortic DNA content=(pg of DNA/mg of aorta)X(mg of aorta/cm of aorta).
Oligonucleosomal DNA fragmentation into 180-to 200-bp integer fragments is a hallmark of apoptosis.27 This specific pattern of DNA fragmentation appears as a "ladder" of DNA fragments after conventional agarose gel electrophoresis in various cell types undergoing apoptosis,*7.** including SMC.21.29-33 To quantify the degree of oligonucleosomal DNA fragmentation in the aortic media, 1 bg of extracted DNA was radiolabeled using terminal deoxynucleotidyl transferase and [32P]dCTP as described previously.26 Because DNA molecules from apoptotic nuclei have an increased number of free 3'OH ends as a result of enhanced endonuclease activity, these show greater incorporation of labeled dCTP. Increasing quantities of radiolabeled DNA (0.025, 0.05, 0.1, 0.2, and 0.4 pg) were loaded in adjacent lanes of 1.5% agarose gels. After electrophoresis, DNA was transferred onto nylon membrane (Hybond N; Amersham) and the radioactivity associated with 150 to 1500 bp DNA fragments was quantified using a PhosphorImager (Molecular Dynamics) (Fig 1A) . The PhosphorImager data were used to construct a regression line for each sample and radioactivity per unit area (cpm per pixel) was plotted as a function of DNA loaded on the gel (pg DNA). We found this approach to be useful in increasing reproducibility of the measurements. Thus, the slope of the linear regression was defined as the "DNA fragmentation Index" (Fig 1B) Commercially available DNA molecular size markers underwent radlolabeling, electrophoresls, and transfer at the same time as the extracted DNA to control for vanabdlty m the procedure Cleavage of DNA mto large fragments (eg, 20 to 50 kbp) at the site of attachment to scaffold proteins has also been described m cells undergoing apaptosls Therefore, radlolabelmg was also quantlfied for DNA fragments of 20 to 30 kbp, as described above DNA synthesis m the aortic media was quantified by measurmg the mcorporation of [3H]thymldme mto the extracted DNA To rule out the posslblhty that drug-induced changes m DNA specific actlvlty (cpm/lOO pg DNA) result from changes m thymldme transport mto the cells rather than changes m DNA synthesis activity per se, the specific activity of the whole aortlc tissue (cpm/mg aorta) was also measured at 1 and 2 weeks of treatment Determination of Smooth Muscle Cell Number SMC number m the aortic media was measured using the three-dimensional dissector method, as adapted from Mulvany et al 18 Briefly, three consecutive sections (5 pm m thickness) were obtained from aortic rings sectioned perpendicularly to the longltudmal axis of the vessel The tissue sections were stained with hematoxyhn, photographed, and prmted at a final magmficatlon of 1000X In the top section, an area, ad, of vessel wall was delineated by two parallel lines approximately perpendlcular to the wall edges A dlsector was defined as the threedimensional probe bounded by ad and the top surface of the "bottom" section The dlsector has volume vd=qXhd, where ad 1s the area of the dlsector and hd 1s the height of the &sector The term hd 1s obtained by the followmg equation hd=(s-l)Xt, where s 1s the number of serial sections and t the average section thickness Within ad, the number of nucleus profiles, n,, was determined and m the subsequent sections, each of the n, nuclei was followed and marked. In the final section, the number of nuclei still present was determined, nb. The number nd=(nr-nb) IS then the number of "downward-pomtmg" nucleus ends within the dlsector when counting from top to bottom Although bmucleate SMC reportedly exist m SHR arteries, these cells account for less than 0 5% of the SMC m the thoraclc aorta of 12-week-old SHR 34 Therefore, on the basis that each cell contains only one nucleus, an estimate of cell numerical density, N,, 1s given by N,=nd/vd The number of cells per unit vessel length then was estimated from a,XN,, where a, 1s the medial cross-sectional area determined with the image analyzer as described above Nuclear length was measured using the followmg equation nuclear length=(n&)Xhd.
Statistical Analysis
Data were analyzed using analysis of variance and unpaired Student's t test with Bonferrom correction for multiple comparisons where appropriate The DNA fragmentation index was analyzed using the nonparametrlc tests Kruskal-Walhs followed by Mann-Whitney because of unequal variance between the groups and because we have no evidence that the mdex is a normally distributed variable Values are presented as mean&SEM, and P< 05 was considered statlstlcally significant
Results
The ability of the antlhypertenslve drugs to reduce vascular hypertrophy and growth m the thoraclc aorta was imtlally examined after 4 weeks of therapy m the SHR (Table 1 ) Drugs that proved effective in reducmg vascular hypertrophy at 4 weeks were selected for the studies at 2 weeks and 1 week of treatment (Table 2) 
Systemic Changes During Drug Administration
Rats used m this study were hypertensive before mltlatlon of therapy, with an average pretreatment value of systolic blood pressure of 176&2 mm Hg (n= 110; no dlfference between control and experimental groups) During the experimental period, systolic pressure increased further m untreated animals, up to 20325 mm Hg at 2 weeks (n=39) and 22025 mm Hg at 4 weeks (n=25) Fig 2A shows the evolution of systolic blood pressure m control and treated rats over the 4-week experimental period Systolic blood pressure was not slgmficantly affected m rats receiving propranolol or HCT for 4 weeks (Fig 2B) but It was slgmficantly reduced m rats receiving either hydralazme (47% reduction m final pressure), losartan (42% reduction), enalaprll (44% reduction), or mfedlpme (23% reduction). Significant reduction m blood pressure was achieved after 1 week with enalaprll or hydralazine, after 2 weeks with losartan, and after 3 weeks with mfedlpme (Fig 2A) . Thus, at the high doses used m this study, the drugs showed the following order of potency for blood pressure reduction: enalaprll zhydralazme >losartan >mfedlpme > >HCT zpropranolol Pretreatment values of body weight were 260~2 g (n=llO). All rats gamed weight during the experimental period but final values of body weight were similar be- At 4 weeks the aorta*body weight ratto was not affected by hydralazme, propranolol, or HCT (Table 1) In contrast, there was a stgmficant reduction m aorttc mass at 4 weeks m rats given losartan (19% reduction), enalapnl (22% reduction), or mfedtpme (26% reduction) Further studies at earlier times revealed a significant reduction m aortic mass as early as 2 weeks with losartan or mfedipme but not enalaprd (Table 2 and Ftg 3A) The aorta of untreated animals showed no increase m vascular mass between ttssues isolated at 1,2, and 4 weeks, suggesting that the druginduced reductions m vascular mass represented a regression rather than a prevention of vascular hypertrophy As a further confirmation that vascular mass was decreased, the aortic cross-secttonal area was stgmficantly decreased by losartan, enalapril, or nifedipme but not hydralazme for 4 weeks (Table 3) To further analyze vascular growth, aorttc DNA content was evaluated per length of vessel The length of the freshly isolated thoracic aorta was 3021 mm (n=26) m untreated animals at 4 weeks, and this value was not affected by any of the treatments studied (not shown). Among all the drugs studied, only losartan and enalaprtl reduced aortic DNA content significantly, by 63% and 66%, respectively, m the aorta after 4 weeks of treatment (Table 1) In contrast, DNA content at 2 weeks showed a significant 60% to 65% reduction with nifedtpme and losartan, and no evidence of reduction with enalapnl (Table  2 and Fig 3B) Administration of losartan or mfedtpme for a shorter period of time (1 week) did not affect total DNA content m the aorta Because the enalaprrl-mduced reduction m DNA content required more than 2 weeks of treatment, this drug was not included m the l-week studies designed to examme apoptosis
Effect of Drugs on SMC Apoptosis
The therapy-induced reduction m DNA content m the thoraclc aorta suggested a stimulatton of apoptosis and a correspondmg reduction m SMC number. To test this hypothesis, the DNA fragmentation index was evaluated as described m "Methods " Losartan caused a threefold to fivefold increase m mternucleosomal DNA fragmentation This effect of losartan was highest at 1 week and sustained as late as 4 weeks after begmnmg of treatment (Tables  1 and 2 , and Fig 3C) . Enalaprtl also stimulated mternucleosomal DNA fragmentation by threefold to fivefold, although the highest effect was observed at 4 weeks In mfedipme-treated rats, mternucleosomal DNA fragmentation was increased at 1 week only The DNA fragmentation index for the large 20-to 30-kbp DNA fragments showed no stgmficant change with treatment (not shown), compared with control values of 1.8-tO 1 cpm per pixel per microgram DNA (n=40).
The three-dimenstonal dtsector method was used to determme whether the reduced DNA content corresponded to a reduced SMC number m the arterial wall (Table 3) In the aorta of untreated rats, we found 116+6 SMC per micrometer of vessel length This SMC number 1s comparable to what Owens 15 reported m the aorta of untreated 3-month-old SHR, using a different method of evaluation We found that the SMC number per length of aorta was stgmficantly reduced by 50% with losartan, by 47% wtth enalaprtl, and by 38% with mfedtpme In contrast, the potent antthypertensive effect of hydralazme dtd not result m reduced SMC number m the arterial wall Thus, there was a highly sigmficant correlation between the aorttc DNA content and the number of SMC m the arterial wall (P< 001; r= 6) Although losartan, enalapril, and nifedtpme sigmficantly reduced the cross-sectional area and therefore the total mass of the aorta, the reduction m SMC number was large enough so that the SMC numerical density was also sigmficantly decreased m the arterial wall (Table 3 ) None of the treatments under study with the disector method affected significantly the average nuclear length of arterial SMC, which was 15tl pm m the untreated aorta, a value comparable with the results obtamed by Mulvany et al 1s m SHR small mesenteric arteries using the same method
Effect of Drugs on DNA Synthesis
As shown m Table 2 , several treatments caused a stgmficant reduction m arterial DNA specific activity wtthout affecting radtoactivtty levels m the whole vascular media (at least at 2 weeks), thus suggesting an mhtbition of SMC DNA synthesis Within 4 weeks, the specific acttvtty of aorttc DNA was decreased by losartan, enalaprtl, and mfedipme but not by hydralazme, propranolol, or HCT (Tables 1 and 2). The kinetic but not the magnitude of the Values are mean?SEM (n=5 to 14 rats). *First occurrence of a significant difference between treated and control groups (PC 05) mhibitory effect vaned between losartan, enalapnl, and mfedlpme ( Fig 3D) . Thus, DNA specific activity was slgnificantly reduced by losartan at 2 and 4 weeks (25% and 3 1% reduction, respectively), by mfedlpme at 2 weeks only (42% reduction), and by enalaprll at 4 weeks only (32% reduction).
Effects of a Lower Dose of Losartan
The regulation of aortlc growth was examined m rats treated with a lower dose of losartan for 4 weeks As shown m Table 4 , admlmstration of losartan (10 mg kg-'. d-') to SHR was unable to reverse the preexisting hypertension but prevented the further development of high blood pressure. Interestmgly, tlus treatment did not result m any slgmficant change m aortic mass, DNA fragmentation, DNA specific activity, or DNA content at 4 weeks Discussion Increased vascular mass is an important feature of hypertensive vessels In the adult SHR, the thoraclc aorta shows medial hypertrophy and a higher SMC DNA content and synthesis rate as compared to normotenslve anlmals.37'734-38 In the absence of high blood pressure, SHR SMC cultured in vitro mamtam an mcreased growth behavior, including hyperresponslveness to growth factors, accelerated entry into S phase of the cell cycle, reduced cell-contact mhibmon, and high mcldence of polyploidy, suggesting a pressure-independent dysregulatlon of growth 39-a We have reported that SMC cultured from SHR aorta also exhibit a heightened propensity to undergo apoptosls, eg, m response to growth factor wlthdrawal.2' We recently reviewed 45 the possible role of apoptosls m regulating vascular mass and DNA content, a hypothesis that has never been examined m hypertensive vessels The balance between SMC DNA synthesis and degradation determines the total DNA content of the arterial media, winch m turn 1s a primary determinant of vascular mass Thus, the aim of the present studies was to investigate the regulation of SMC apoptosls during the regression of aortic medial hypertrophy induced by antihypertensive therapy m the SHR
Time Window of Apoptosis
Within 4 weeks of effective antlhypertensive therapy, we observed a reduction m aortlc mass m rats treated with losartan, enalapnl, or mfedlpme but not hydralazine Several lines of evidence suggest that the regression of vascular hypertrophy was associated with increased SMC apoptosls. First, there was a marked increase m mtemucleosomal fragmentation of the DNA m the aortic media. This specific pattern of DNA is a hallmark feature of apoptosis observed m several types of cells*7 mcludmg SMC m culture 21.30-33 Second, there was a slgmficant reduction m aortlc DNA content in the weeks followmg the ml&al burst of mternucleosomal DNA fragmentation Finally, the number of SMC m the aortic wall was reduced after 4 weeks of losartan, enalapnl, or mfedlpme but not hydralazme, m correlation with the effects of these drugs on aortic DNA content. The present data on the kinetics of artenal SMC apoptosis during drug therapy are remmlscent of our recent observations m the heart adapting to pressure overload caused by aortic coarctatlon.26 In this model, the development of cardiac hypertrophy is preceded by a transient mcrease m apoptosls, notably m cardlomyocytes We suggested that the design of therapeutic approaches aimed at controlling cardiovascular remodeling should take mto account the presence of time windows of apoptosls during pathogenesis.46 The present studies provide evidence that wmdows of rapid change m apoptosls also occur m response to drug therapy.
SMC Apoptosis and Blood Pressure
The stlmulatlon of SMC apoptosls could be dissociated from the antihypertensive effects of the drugs tested Although hydralazme was very effective at reducing hypertennon, it did not affect DNA fragmentation, DNA content, SMC number, or vascular mass at 4 weeks Furthermore, the stimulation of SMC apoptosls was more rapid with losartan or mfechpme (1 week) than with enal- In VIVO The data were taken from Tables 1 and 2 , expressed as a percentage of the corresponding control values and plotted as a function of time after mltlatlon of drug therapy april (2 weeks), whereas blood pressure reduction was pressure reductron Consistent wrth this, calcium channel more rapid and pronounced with enalapnl (1 week) than blockers stimulate apoptosrs independently of hemodywith losartan (2 weeks) or nrfedrpme (>2 weeks) Taken namic changes m cultured SMC.47 together, these data strongly suggest that drug-induced Several groups reported a dissocration between blood SMC apoptosis was not a secondary response to blood pressure reduction and aortrc mass regression m the SHR on the basis of comparattve studies between hydralazme and losartan,48 a calcium channel blocker,49 or an ACE mhtbnor 5" The present results extend these findings by showing that mfedtpme induced aortic mass regression before systohc pressure reduction (ie, at 2 and 3 weeks, respectively) Increased SMC apoptosrs may account for this early structural effect of the calcium channel blocker SMC apoptosts may also contribute, along with vasodilatatton51 and decreased extracellular matnx accumulauon,5* to mcrease the compliance of large conduit arteries m response to ACE mhtbttors, AT1 antagonists or calcmm channel blockers, a major beneficial effect of these drugs agamst left ventrtcular hypertrophy and systolic hypertension.22~53 The available evidence from previous studies suggests that m SHR the antihypertensive and antthypertrophtc effects of P-blockers and dmrettcs are modest, slow to develop, and may be more pronounced when the drugs are administered before hypertension 1s establlshed.*4,75.54-5" Thus, although propranolol and HCT dtd not significantly affect blood pressure or vascular structure at this established phase of SHR hypertension, we cannot rule out that an earlier or more prolonged schedule of admmtstration may affect arterial SMC apoptosis SMC Apoptosis and DNA Synthesis Heightened DNA replication rates are often associated with and even counterbalanced by an increase m SMC apoptosrs Cho et al*9 reported that high rates of DNA synthesis m specific arteries of the neonatal lamb do not translate to a correspondmg increase m vascular DNA content In these arteries which show regression after birth the high rates of SMC DNA synthesis are counterbalanced by heightened apoptosts SMC apoptosrs IS also markedly mcreased in the developing neomtimal lesion after balloon catheter mJury m rats 57~8 Apoptosrs and DNA replication are both found mainly among SMC located near the lummal surface of the neomtima, suggesting that apoptosrs may regulate the cellularity of the lesion m the face of chronic cell proliferation 59 Bennett et a130 reported that SMC overexpressmg the proto-oncogene and growth-related transcnphon factor c-myc showed an increased rate of DNA rephcatton that was resistant to mhibmon by serum wrthdrawal or mterferon-y In an apparent paradox, however, serum withdrawal or interferon-y indeed abolished the accumulatton of c-myc cells This discrepancy between the high rates of DNA synthesis and the low rates of cell accumulation could be explained by the markedly increased frequency of apoptosts m the c-myc cells m response to serum withdrawal or interferon-y treatment Thus, c-myc overexpression stimulates both cell proliferation and death by apoptosts, and the balance between prollferation and death is controlled by survival and cytostatic signals from the environment Overall, the data on SMC apoptosrs regulation suggest that the need for survival signals may be increased m cells stimulated to undergo replication It is mtrigumg to speculate that the early increase m aortic SMC apoptosrs, preceding the mhtbmon of DNA synthesis, represented a failure of SMC to adapt rapidly to reduced levels of survival factors such as angrotensm II or extracellular calcium influx Several groups reported that the aorta of SHR has an increased percentage of polyplotd SMC, a feature which correlates m part with the severity of hypertension and which is srgmficantly reduced by ACE mhibitors or losartan but not hydralazme or diuretics 7 16384360 Assuming equal frequencies of apoptotrc cell death among diplotd and tetraplotd SMC, the decrease m aortic DNA content would overestimate SMC mortality by one third Indeed, in the present study treatment with losartan caused a greater reduction m DNA content than m SMC number m the aorta after 4 weeks (63% reduction m DNA versus 47% reduction m cellularity, respectively). A similar pattern was observed with enalaprtl (66% versus 50% reduction, respectively) In contrast, mfedipme caused a smaller reduction m DNA content than m SMC number (25% versus 38% reductron, respecttvely). It is mtrtgumg to speculate that these differences may reflect differential rates of apoptosts m polyplotd versus diploid SMC Clearly, further studies are needed to mvestigate apoptosis regulation and arterial SMC polyploidy.
Detailed studies by Owens35 did not detect a change m vascular DNA content or SMC number m the aorta of SHR treated with the ACE mhibrtor captoprrl Differences m experimental design may explain the discrepancies between the latter and present studies First, captoprrl was administered to SHR for 3 months begmmng at 2 months of age, re, before the onset of hypertension In contrast, rats used m the present study were already hypertensive when drug therapy was mutated and then aorta was examined at earlier times thereafter Second, we observed a marked reduction of the preexistmg hypertension (at least with mhtbitors of the angtotensm II pathway), whereas the treatment with captopr1135 mainly prevented the development of high blood pressure over time It 1s mtrtgumg to speculate that sttmulation of SMC apoptosrs m the arterial media may require aggressive antihypertensive therapy causing abrupt yet specific changes m the homeostatic environment of the cells m the arterial wall. In support of this view, we showed that a lower dose of losartan that prevented, but did not reverse, the progresston of hypertension m SHR failed to affect aortic mass, DNA fragmentation index, or DNA content at 4 weeks. Previous studies support the view that rates of blood pressure change over time may be critical m determining SMC growth behavior For instance, the gradual increase in blood pressure m SHR, Goldblatt rats, and DOCA-salt and norepmephrme-induced models of hypertension results m increased aorttc SMC polyploidy is,16 In contrast, the abrupt increase m intra-aortic blood pressure that follows suprarenal aortic coarctation is associated with the rapid and sigmficant increase m aortic SMC hyperplasia.61 The regulation of SMC apoptosis m normotensive rats, which show less prominent hemodynamic responses to antihypertensive drugs than SHR, remains to be determined An additional though nonexclusive possibihty is that the depletion of SMC m the arterial wall is transtent and reversible within the first months of drug therapy Indeed, our data with mfedipme at 2 and 4 weeks (Fig 3) are consistent with such a complex regulation of SMC growth in the arterial wall. Ultimately, it is conceivable that vascular remodeling without a net change in vascular mass or cell number (eutrophic vascular remodeling)62 may result from the reversible depletton of SMC via a balanced process of SMC apoptosis and rephcation.
Molecular Mechanisms Regulating SMC, Apoptosis
It is important to note that the tnggermg of apoptosts 1s dependent on a balance of environmental cues that are far from bemg specific to apoptosis In vitro studies have identrfied several factors that can modulate, m parallel or m opposition, SMC DNA replication and apoptosis. For mstance, DNA replication is mhibned and apoptosis is mcreased via the CAMP pathway, the mtrtc oxide pathway, interferon-y, or calcium channel blockers 21,32,33.47,47.63 In contrast, platelet-dertved growth factor or msuhn-like growth factor-l mhtbits apoptosis and promotes DNA rephcation.31,64,65 In addition, overexpression of the transcription factor c-myc or its adenovtral functional homologue ElA increases both DNA rephcation and apoptosis m SMC.6657 Finally, basic fibroblast growth factor and epidermal growth factor stimulate DNA replicatton without affecting SMC apoptosis.31*"8 We have recently reported further evidence for the independent regulation of DNA synthesis and cell death by apoptosis in cultured SMC 69 To our knowledge, the present study is the first to describe the regulation by pharmacological agents of arterial SMC apoptosis in viva Angiotensin II acting via AT, receptors may act as a survival factor for SMC. Both the ACE inhibitor enalapril and the angiotensm II AT, receptor antagonist losartan potently increased SMC apoptosis m the aorta Angiotensm II bmdmg to AT, receptors may inhibit SMC apoptosis either directly or indirectly by stimulating the production of autocrme survival factors, mcludmg platelet-derived growth factor and msulm-like growth factor-1,3JJ+6J or by stimulatmg the production of specific extracellular matrix molecules, such as osteopontm,70 m the arterial wall. Disruption of bmdmg to the ay,p3 mtegrm receptor for osteopontm induces apoptosis m angtogemc blood vessels 71 In fact, a growing body of evidence suggests that extracellular matrix proteins regulate apoptosis by interacting with cellular mtegrm receptors and modulatmg intracellular protein tyrosme phosphatase activity 72 Stimulation of the AT2 receptor subtype for angiotensm II is a potential pathway for the rapid stimulatton of SMC apoptosis m losartan-treated animals, a condition where plasma levels of angiotensm II are markedly mcreased.73 Recently, the angiotensin AT2 receptor subtype has been implicated in the reduction of high blood pressure,74J5 the mhibition of arterial SMC DNA replication,76 and the inductton of apoptosis m fibroblasts, ovarian cells and neuronal cells via the activation of protein tyrosine phosphatase pathways.77Js
Enalapnl effects on SMC apoptosis, DNA synthesis, and vascular mass were comparable m magmtude though delayed compared with losartan, which was the most potent inducer of apoptosis or mhtbitor of DNA synthesis The faster onset for blood pressure reduction with enalapril may involve the reduced breakdown of endogenous vasodilatory kmms.7" Effects of kmms on apoptosis are unknown, but tt 1s possible that kmm-induced secretion of NO by endothehal cells may contribute to stimulate SMC apoptosis in viva 63
Ntfedipme had a transient effect on arterial growth and apoptosis. Recent retrospective epidemtological studies suggested that treatment of hypertensive patients with rapidly acting formulations of mfedipine (as m the present study) might increase the risk of coronary mortality*0 or cancer 81 In the latter study, mhibmon of apoptotic cell death by nifedipme was proposed as a putative mechanism for the promotion of neoplastic growth. The present study does not provide evidence supportmg this hypothesis Clearly, these clinical issues remain to be clarified within the framework of prospective studies Notably, it remains unclear whether the putative risk increases might represent a class effect of calcium channel blockers, a secondary effect related to sympathetic acttvation with short acting formulations of mfedipmeQ (m the case of coronary mortality), or simply a medication-independent association between hypertension and cancer 83 The present data suggest that antihypertensive medrcattons have complex effects on growth and apoptosis which need to be explored further m the long term.
It has been suggested that long-term benefits from antihypertensive therapies may depend on the remodeling of vascular structure with the normahzatton of wall-to-lumen ratio. lo-12 Recent studies in hypertensive humans indicated that blood pressure reduction is accompanied with significant remodeling of small muscular arteries in patients treated with ACE mhibitors or a calcmm channel antagonist but not P-blockers 84-86 The present studies suggest that SMC apoptosis 1s one of the earliest events m the sequence of changes taking place during drug-induced regression of vascular hypertrophy It remains unclear what is the long-term significance of apoptosis on SMC population dynamics in the arterial wall. Another critical question is whether the regulatton of apoptosis is vessel specific, as it has been suggested for SMC growth behavior 7037 In summary, nifedipme and mhibitors of the angiotensm pathway stimulated SMC apoptosis early during regression of vascular hypertrophy m the thoracic aorta, before SMC DNA replication was mhibited, and independently of blood pressure reduction. Thus, a major goal of research should be to better characterize mechamsms regulating apoptotic SMC death m vtvo and its putative role in hypertensive vessel remodeling rn disease and m response to therapeutic agents. 
